Abstract | BACKGROUND: PROCEDURE: Patients with ALL or lymphoblastic lymphoma (LBL; N = 1368) who developed a hypersensitivity reaction (grade ≥2) to an E. coli-derived asparaginase participated in this trial. The recommended asparaginase Erwinia chrysanthemi dose was 25,000 IU/m(2) three days per week (Monday/Wednesday/Friday) for two consecutive weeks for each missed pegylated E. coli-derived asparaginase dose and 25,000 IU/m(2) for each missed nonpegylated asparaginase dose for the completion of their planned asparaginase treatment. RESULTS: Adverse event reports and/or case report forms were completed for 940 patients. The most common adverse event (AE) was hypersensitivity (13.6%). Eighteen patients (1.9%) died during the study. Most patients (77.6%) completed their planned asparaginase treatment with asparaginase Erwinia chrysanthemi. There was no apparent difference in the incidence of the most commonly reported AEs with asparaginase treatment by age, administration, or disease state. CONCLUSIONS:
|
Authors | Paul V Plourde, Sima Jeha, Nobuko Hijiya, Frank G Keller, Lewis B Silverman, Susan R Rheingold, ZoAnn E Dreyer, Gary V Dahl, Taheri Mercedes, Chinglin Lai, Tim Corn |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 61
Issue 7
Pg. 1232-8
(Jul 2014)
ISSN: 1545-5017 [Electronic] United States |
PMID | 24436152
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 Wiley Periodicals, Inc. |
Chemical References |
- Antineoplastic Agents
- Bacterial Proteins
- Recombinant Proteins
- Asparaginase
|
Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Asparaginase
(administration & dosage, adverse effects)
- Bacterial Proteins
(administration & dosage, adverse effects)
- Child
- Child, Preschool
- Dickeya chrysanthemi
(enzymology)
- Dose-Response Relationship, Drug
- Drug Hypersensitivity
(etiology, mortality)
- Female
- Humans
- Infant
- Male
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, mortality)
- Recombinant Proteins
(administration & dosage)
|